Archer Investment Corporation’s Novavax NVAX Stock Holding History

Archer Investment Corporation’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-475	Closed	-$4.88K	–	885
2022 Q4	$4.88K	Buy	+475	New	+$8.38K	﹤0.01%	630

Other funds holding NVAX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Archer Investment Corporation's NVAX Position: Q1 2023 in Review

Archer Investment Corporation sold out of Novavax (NVAX) in Q1 2023, closing a stake of 475 shares — an estimated $4.88K sold.

Archer Investment Corporation first reported a position in NVAX in Q4 2022 and held it in 1 quarter. The position peaked at $4.88K in Q4 2022. 223 funds tracked by Wall St. Rank hold NVAX as of Q1 2023.

Archer Investment Corporation reported no remaining Novavax position as of Q1 2023 after selling out during the quarter.
Archer Investment Corporation sold 475 Novavax shares in Q1 2023, an estimated $4.88K.
Archer Investment Corporation first reported a position in Novavax in Q4 2022 and held it in 1 quarter.
Archer Investment Corporation's Novavax position peaked at $4.88K in Q4 2022.
223 funds tracked by Wall St. Rank held Novavax as of Q1 2023.

Based on Archer Investment Corporation's 13F filing for Q1 2023, filed 9 May 2023.